What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2025-11-17 compared with 2025-08-05 · 20 added, 24 removed, 20 unchanged (69% of the section changed)

OTHER INFORMATION

12, 2025 , Nicholas

Alvarez , Chief

Acquisition Officer , terminated

a Rule 10b5-1 trading arrangement adopted

on March 13, 2025 , that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 300,000 shares

of the Company’s common stock, at various limit prices above the current market price of the Company’s common stock as

of the plan adoption date, with such transactions to have occurred during sale periods beginning on or after July 1, 2025 and ending

on the earlier of April 10, 2026 or the date on which all shares authorized for sale would have been sold in conformance with the

terms of the arrangement.

Date/Period End Date

Confidential Offer Letter, dated April 14, 2021 between LifeMD, Inc.

and Shayna Webb Dray

First Amendment to Employment Agreement, dated November 8, 2023 between LifeMD, Inc.

and Shayna Webb Dray

Second Amendment to Employment Agreement, dated May 7, 2024 between LifeMD, Inc.

and Shayna Webb Dray

Third Amendment to Employment Agreement, dated July 27, 2025 between LifeMD, Inc.

and Shayna Webb Dray

Restricted Stock Unit Award Agreement, dated July 27, 2025, between LifeMD, Inc.

and Shayna Webb Dray

Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.

Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer.

Section 1350 Certification of Chief Executive Officer.

Section 1350 Certification of Chief Financial Officer.

August 22, 2025 , Eric Yecies , Chief Legal Officer and General Counsel , adopted a Rule 10b5-1 trading arrangement that is intended to

satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 200,000 shares of the Company’s common stock, at various

limit prices above the current market price of the Company’s common stock as of the plan adoption date, with such transactions

to occur during sale periods beginning on or after November 21, 2025 and ending on the earlier of December 31, 2026 or the date on which

all shares authorized for sale have been sold in conformance with the terms of the arrangement.

described in Part 1, Item 4.

Controls and Procedures, we have identified an additional material weakness in our internal control over

financial reporting as of September 30, 2025.

We have concluded that this material weakness also existed as of December 31, 2024, March

31, 2025 and June 30, 2025.

Accordingly, the previous conclusion included in Item 9A of our Form 10-K filed with the Securities and Exchange

Commission on March 11, 2025 that our disclosure controls and procedures and internal control over financial reporting were ineffective

is hereby updated to include this additional material weakness.

Also, the previous conclusions included in Item 4 of our Forms 10-Q filed

with the Securities and Exchange Commission on May 6, 2025 and August 5, 2025 that our disclosure controls and procedures was ineffective

is hereby updated to also include this additional material weakness.

13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.

13a-14(a) / 15d-14(a) Certification of Chief Financial Officer.

1350 Certification of Chief Executive Officer.

1350 Certification of Chief Financial Officer.

XBRL Instance Document

18 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information